Went Philip T, Sauter Guido, Oberholzer M, Bubendorf Lukas
Institutes for Pathology, University of Basel, Switzerland.
Pathology. 2006 Oct;38(5):426-32. doi: 10.1080/00313020600922470.
Alpha-methylacyl-CoA racemase (AMACR), a mitochondrial and peroxisomal enzyme, is a valuable tool to confirm the diagnosis of prostate cancer, especially if combined with basal cell markers. To extend this diagnostic utility to other neoplasias, we comprehensively surveyed AMACR expression in human tumours.
We performed immunohistochemical analyses on tissue microarrays of AMACR expression in over 125 different human tumour types and 80 normal tissues.
Microarray analysis revealed that tumours with prominent AMACR expression included adenocarcinomas of the prostate (72%), hepatocellular carcinomas (77%), papillary renal cell carcinomas (70%), and colorectal adenocarcinomas (71%). AMACR expression was equally frequent in colorectal adenomas and carcinomas. No significant difference in AMACR expression between untreated and hormone-refractory prostate cancers was observed. In the thyroid, AMACR expression was found in 42% of the follicular carcinomas but in only 16% of follicular adenomas. However, a more detailed analysis on a thyroid tissue microarray did not confirm a significant difference of AMACR expression in follicular adenoma and carcinomas.
Taken together, the results indicate that AMACR is expressed in a wide variety of adenocarcinomas, and its diagnostic utility is restricted to specific areas.
